Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01488552|
Recruitment Status : Completed
First Posted : December 8, 2011
Last Update Posted : August 18, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Stage IV Pancreatic Cancer||Drug: Gemcitabine Drug: nab-paclitaxel Drug: FOLFIRINOX Genetic: Immunohistochemistry (IHC) Analysis Drug: Metformin Drug: mFOLFIRI||Phase 1 Phase 2|
The investigators in the PCRT team have developed a therapeutic regimen which attacks both the tumor compartment and the stromal compartment of pancreatic cancer and induces complete responses in a small percentage of patients with advanced stage IV pancreatic cancer.
The gemcitabine + nab-paclitaxel regimen had outstanding activity in a 67 patient phase I/II trial with all patients at the recommended phase II doses (n=44) having a decrease in CA19-9, some complete responses and a median survival of 12.2 months. The proposed regimen that is devised for this study is a bold, innovative approach with the specific aim of utilizing a relentless pursuit approach to try to make the complete response rate >70% and have this response be durable (which the PCRT has defined as lasting at least 6 months) and to dramatically enhance the percent of patients who survive one year (try to make the rate >70%).
The induction regimen the investigators propose collapses the stroma (gemcitabine + nab-paclitaxel) and addresses the use of a non-cross resistant active regimen (FOLFIRINOX) as a consolidation regimen. Both should improve the chance of driving tumor markers down dramatically. The investigators think that FOLFIRINOX with the stromal collapse induced by the initial regimen, plus the totally non-cross resistant shot against the disease (consolidation), will maximize the chance of achieving a complete response with an attendant improvement in survival.
After the consolidation, the patient will be maintained on a less toxic targeted therapy selected by molecular profiling plus the use of the antimetabolomic agent metformin which has consistently been associated with better survival in multiple retrospective studies (Jiralerspong et al., 2009).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||August 2015|
|Actual Study Completion Date :||August 2016|
Experimental: Gemcitabine & Abraxane Pancreatic Cancer
Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Other Name: Gemzar
125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Other Name: Abraxane
The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;
Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Genetic: Immunohistochemistry (IHC) Analysis
Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
Other Name: Glucophage
5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
- Complete Response Rate [ Time Frame: 1 yr. ]
The primary objectives of this study are to relentlessly pursue treatment for 34 individual patients with Stage IV pancreatic cancer to obtain:
• The complete response rate (as defined by a complete metabolomic response (CMR) of SUV normalization from baseline, OR a complete response on CT scan using a modified RECIST criteria and CA 19-9 (or CA 125, CEA, or PAM4 if not expressers of CA 19-9) down to normal limits (from at least > 2X ULN).
- One-Year Survival Endpoint [ Time Frame: 1 yr. ]
A secondary objective of this study is to:
Observe the percent of patients who are alive at one year (our goal is to obtain a >70% one year survival.)
- Efficacy Endpoints using biomarkers [ Time Frame: 1 yr. ]
A secondary objective of this study is to:
Gather information on other possible efficacy endpoints (e.g. CA 19-9) and other serum/plasma tumor markers
- Observing toxicity outcomes [ Time Frame: 1 yr. ]A secondary objective of this study is to document the toxicities noted in all patients, particularly with those who receive the FOLFIRINOX regimen. Grade 3-4 neutropenia is expected to be > 40% among those receiving FOLFIRINOX, so to minimize toxicity, all patients will receive prophylactic CGSF. In the first 9 patients receiving FOLFIRINOX, if the hospitalization rate due to toxicity is more than 50% (5 or more patients), then all subjects will have a dose reduction to level -1. The incidence of grade 3 and 4 toxicities and dose delays will also be considered for dose modification.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically documented Stage IV metastatic adenocarcinoma of the pancreas with measurable disease
- Performance status ECOG 0 or 1
- Patients may not have received prior treatment for metastatic pancreatic adenocarcinoma except for receiving gemcitabine or 5FU as a radiosensitizer along with radiation therapy; or have received gemcitabine for adjuvant treatment if they have been off gemcitabine for > 12 months
- Adult (>18 years of age) male or non-pregnant and non-lactating female
- A negative serum pregnancy test (Beta-hCG) documented within 72 hours of the first administration of study drug in female patients of child-bearing potential
- Agreement to use contraception considered adequate and appropriate by the investigator
The following blood counts at baseline:
- ANC >/= 1.5 x 109/L
- Hgb > 9g/dL
- Platelets >100 x 109/L
The following blood chemistry levels at baseline:
- AST and ALT </= 2.5 x upper limit of normal range (ULN) or < 5.0 ULN if liver metastasis are present
- Bilirubin </= ULN
- Serum creatinine within 1.5 x ULN
- PT, INR within 1.5 x ULN unless on therapeutic doses of warfarin
- Must have measurable disease outside the pancreas by RECIST criteria
- No clinically significant abnormalities in urinalysis results
- Voluntary agreement to participate in this study after being informed about the nature of the study including potential risks and benefits and having the ability to have questions addressed. The patient must sign and date the IRB approved Informed Consent Form (ICF) prior to participation in any study-related procedures
- Has pancreatic islet cell neoplasms
- Is pregnant or lactating
- Has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- Known infection with HIV, Hepatitis B or Hepatitis C.
- Patient with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies (see section 4.4.9)
- Has a serious medical risk factor(s) involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.
- Is unwilling or unable to comply with study procedures.
- Is enrolled in any other investigational trial.
Caution of observation for interstitial pneumonitis in patients prior to enrollment:
Before enrollment, evaluate candidate patients fro familial, environmental or occupational exposure to opportunistic pathogens, and do not enroll those with a history of slowly progressive dyspnea and unproductive cough, or of conditions such as sarcoidosis, silicosis. idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01488552
|United States, Arizona|
|TGen Clinical Research Services (TCRS)|
|Scottsdale, Arizona, United States, 85258|
|United States, California|
|Disney Family Cancer Center|
|Burbank, California, United States, 91505|
|United States, Minnesota|
|Virginia Piper Cancer Institute (VPCI)|
|Minneapolis, Minnesota, United States, 55407|
|United States, Washington|
|Virginia Mason Medical Center|
|Seattle, Washington, United States, 98101|
|Evergreen Hematology and Oncology|
|Spokane, Washington, United States, 99218|
|Principal Investigator:||Ramesh K Ramanathan, MD||Translational Genomics Research Institute|
|Responsible Party:||Pancreatic Cancer Research Team|
|Other Study ID Numbers:||
|First Posted:||December 8, 2011 Key Record Dates|
|Last Update Posted:||August 18, 2016|
|Last Verified:||August 2016|
Stage IV pancreatic cancer
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Endocrine System Diseases
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs